medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2020, Number S1

<< Back Next >>

Rev Latin Infect Pediatr 2020; 33 (S1)

Treatment for COVID-19

Mercado RJY, Taborda MJ, Ochoa GE, Carreto BLE, Maldonado TB, García CER, Monsiváis OAC, Garrido GC

Language: Spanish
References: 32
Page: 42-51
PDF size: 261.63 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Calvo Rey C, García-López Hortelano M, Tomás Ramos J, Baquero Navarro F, Navaro M et al. Documento de manejo clínico del paciente pediátrico con infección por SARS-CoV-2. Extracto del Documento de Manejo Clínico del Ministerio de Sanidad [Internet]. Sociedad Española de Infectología Pediatrica; 2020 [actualizado 18 de agosto 2020]. p. 1-17. Disponible en: https://www.analesdepediatria.org/contenidos/pdf/Recomendaciones_pediatricas_Covid1.pdf

  2. Acuña Cordero R, Bejarano Melo MA, Niederbacher Velásquez J, Pulido Fentanes S, Restrepo Gualteros SM, Villamil Osorio M. COVID-19 en niños, Colombia, versión 2 [Internet]. Asociación Colombiana de Neumología Pediátrica. 2020 [actualizado 1 de abril 2020]. pp. 1-18. Disponible en: https://scp.com.co/wp-content/uploads/2020/04/Coronavirus-Version-2.pdf.pdf

  3. PAHO. Ibuprofeno y COVID-19. 18 de marzo de 2020 [Internet]. Disponible en: https://www.paho.org/es/documentos/ibuprofeno-covid-19-washington-dc-18-marzo-2020

  4. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun [Internet]. 2020; 11 (1): 222. Available from: https://www.nature.com/articles/s41467-019-13940-6.pdf

  5. Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI et al. Arguments in favor of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents [Internet]. 2020; 55 (4): 105933. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135364/pdf/main.pdf

  6. Fung KL, Chan PL. Comment on: COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother [Internet]. 2020; 75 (7): 2016-2017. Available from: https://watermark.silverchair.com/dkaa114.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAoUwggKBBgkqhkiG9w0BBwagggJyMIICbgIBADCCAmcGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMc4x2Yqwh72fM9crwAgEQgIICOIO48ZhtTNBuT4CUDqQKdX5BJeQzz2ylqhCQHQxXFl5WBU3

  7. Ministerio de Sanidad de España. Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 [Internet]. Agencia Española de Medicamentos y productos. 2020 [actualizado 9 julio 2020]. Disponible en: https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid‑19/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2/

  8. Mulangu S, Dodd LE, Davey RT, Mbaya OT, Proschan M, Mukadi D et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019; 381 (24): 2293-2303.

  9. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science [Internet]. 2020; 368 (6490): 473-474. Disponible en: https://science.sciencemag.org/content/368/6490/473/tab-pdf

  10. Xu X, Han M, Li T, Sun W, Wang D, Fu B et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A [Internet]. 2020; 117 (20): 10970-10975. Disponible en: https://www.pnas.org/content/pnas/117/20/10970.full.pdf

  11. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev [Internet]. 2020; 19 (6): 102537. Available from: https://reader.elsevier.com/reader/sd/pii/S1568997220300926?token=F43051E26D5C53F4DE8F257892A8DBF643EB879C8411430E98984B12870174888533157A0154AFCEE2A391CA5041D254

  12. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020; 5 (1): 17-19.

  13. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv [Internet]. 2020. doi: https://doi.org/10.1101/2020.03.06.20032342. Disponible en: https://www.medrxiv.org/content/10.1101/2020.03.06.20032342v1.full.pdf+html

  14. Gautret P, Lagier JC, Parola P, Thuan Hoang V, Meddeb Line et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis [Internet]. 2020; 34: 101663. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151271/pdf/main.pdf

  15. González-Castro A, Escudero-Acha P, Peñasco Y, Leizaola O, Martínez de Pinillos Sánchez V. Cuidados intensivos durante la epidemia de coronavirus 2019. Med Intensiva [Internet]. 2020; 44 (6): 351-362. Disponible en: https://www.medintensiva.org/contenidos/pdf/MEDIN_1476.pdf

  16. Xing Q, Li G, Xing Y, Chen T, Li W, Ni W et al. Precautions are needed for COVID-19 patients with coinfection of common respiratory pathogens. medRxiv [Internet]. 2020. Disponible en: https://www.medrxiv.org/content/10.1101/2020.02.29.20027698v2.full.pdf

  17. Calvo C, García López-Hortelano M, de Carlos Vicente JC, Vázquez Martínez JL. Recomendaciones sobre el manejo clínico de la infección por el «nuevo coronavirus» SARS-CoV2. Grupo de trabajo de la Asociación Española de Pediatría (AEP). An Pediatr (Barc) [Internet]. 2020; 92 (4): 241.e1-241.e11. Disponible en: https://www.analesdepediatria.org/es-pdf-S169540332030076X

  18. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ [Internet]. 2020. doi: 10.1136/bmj.m1256. Disponible en: https://www.bmj.com/content/bmj/368/bmj.m1256.full.pdf

  19. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A [Internet]. 2020; 117 (17): 9490-9496. Disponible en: https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf

  20. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA [Internet]. 2020; 323 (16): 1582-1589. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2763983

  21. Connors J, States U, Levy J, States U. COVID-19 and its implications for thrombosis and anticoagulation COVID-19 and its implications for thrombosis and anticoagulation. Blood [Internet]. 2020; 135 (23): 2033-2040. Disponible en: https://watermark.silverchair.com/bloodbld2020006000c.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA5YwggOSBgkqhkiG9w0BBwagggODMIIDfwIBADCCA3gGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMldh6BiJ17AdXg5OnAgEQgIIDSQH3Uekf0--0Kqm1oviDuxBcdJ0P7WmvB0H

  22. Zou H, Xiong WF. Advances in the relationship between coronavirus infection and coagulation function. Chin Med J (Engl) [Internet]. 2020; 133 (12): 1489-1490. Disponible en: https://journals.lww.com/cmj/Citation/9000/Advances_in_the_relationship_between_coronavirus.99322.aspx

  23. Newall F, Branchford B, Male C. Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues. J Thromb Haemost. 2018; 16 (2): 196-208.

  24. Whittle JS, Pavlov I, Sacchetti AD, Atwood C, Rosenberg MS. Respiratory support for adult patients with COVID-19. J Am Coll Emerg Physicians Open [Internet]. 2020; 10.1002/emp2.12071. Disponible en: https://onlinelibrary.wiley.com/doi/pdf/10.1002/emp2.12071

  25. Pastor Vivero MD, Pérez Tarazona S, Rodríguez Cimadevilla JL. Fracaso respiratorio agudo y crónico. Oxigenoterapia. Protoc Diagn Ter Pediatr. 2017; 1: 369-399.

  26. Bugarín González R, Martínez Rodríguez JB. La oxigenoterapia en situaciones graves [Internet]. Medicina Integral. 2000; 36 (5): 159-165. Disponible en: https://www.academia.edu/36414966/La_oxigenoterapia_en_situaciones_graves

  27. World Health Organization. Oxygen therapy for children. Geneva: World Health Organization; 2016. pp. 1-57. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/204584/9789241549554_eng.pdf;jsessionid=3771BCCE16FF08061123B70DF03F9F4F?sequence=1

  28. Luna Paredes MC, Asensio De La Cruz O, Cortell Aznar I, Martínez Carrasco MC, Barrio Gómez De Agüero MI, Pérez Ruiz E et al. Oxygen therapy in acute and chronic conditions: Indications, oxygen systems, assessment and follow-up. An Pediatr. 2009; 71 (2): 161-174.

  29. Lyons C, Callaghan M. The use of high-flow nasal oxygen in COVID-19. Anaesthesia [Internet]. 2020; 75 (7): 843-847. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.1111/anae.15073

  30. Jie L. Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia. Chinese J Tuberc Respir Dis. 2020; 17: E020.

  31. Olveira C, Muñoz A, Domenech A. Terapia nebulizada. Año SEPAR. Arch Bronconeumol. 2014; 50 (12): 535-545.

  32. Canesí Gómez C, Peñuelas Rodríguez O. Recomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infección por SARS-CoV-2. Rev Esp Anestesiol Reanim [Internet]. 2020; 67 (5): 261-270. Disponible en: https://www.elsevier.es/es-revista-revista-espanola-anestesiologia-reanimacion-344-pdf-S0034935620300785




2020     |     www.medigraphic.com